HC Wainwright Lowers Earnings Estimates for vTv Therapeutics

Key Points

• HC Wainwright lowered its earnings forecasts for vTv Therapeutics, projecting a Q3 2026 loss of $1.01 per share versus its prior $0.54 estimate and losses through 2030.
• Despite the estimate cuts, HC Wainwright maintained a Buy rating and $42 price target. Analysts overall assign the stock a “Moderate Buy” consensus rating with an average target of $55.83.
• vTv Therapeutics reported a quarterly loss of $1.05 per share, missing the $0.97 consensus estimate, while Wall Street Zen downgraded the shares to Sell.

vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) - HC Wainwright decreased their Q3 2026 earnings per share estimates for vTv Therapeutics in a report released on Thursday, August 6th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will post earnings of ($1.01) per share for the quarter, down from their previous estimate of ($0.54). HC Wainwright currently has a "Buy" rating and a $42.00 price target on the stock. The consensus estimate for vTv Therapeutics' current full-year earnings is ($2.52) per share. HC Wainwright also issued estimates for vTv Therapeutics' Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($4.60) EPS, FY2028 earnings at ($4.40) EPS, FY2029 earnings at ($3.78) EPS and FY2030 earnings at ($3.61) EPS.

A number of other equities analysts have also weighed in on VTVT. Weiss Ratings upgraded shares of vTv Therapeutics from a "sell (d-)" rating to a "sell (d+)" rating in a research report on Monday, May 18th. Wall Street Zen downgraded shares of vTv Therapeutics from a "buy" rating to a "sell" rating in a report on Saturday. Zacks Research lowered shares of vTv Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, June 11th. BTIG Research raised their target price on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a "buy" rating in a research note on Thursday, July 16th. Finally, Rodman & Renshaw began coverage on vTv Therapeutics in a report on Tuesday, June 30th. They set a "buy" rating and a $67.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, vTv Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $55.83.

vTv Therapeutics Price Performance

vTv Therapeutics stock opened at $35.37 on Monday. The company has a fifty day simple moving average of $33.40 and a 200-day simple moving average of $34.80. The firm has a market capitalization of $139.36 million, a price-to-earnings ratio of -33.37 and a beta of 0.29. vTv Therapeutics has a 52-week low of $14.00 and a 52-week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.08).

Institutional Investors Weigh In On vTv Therapeutics

A number of hedge funds have recently modified their holdings of VTVT. Goldman Sachs Group Inc. purchased a new position in vTv Therapeutics during the fourth quarter worth about $221,000. 683 Capital Management LLC purchased a new stake in shares of vTv Therapeutics in the 4th quarter valued at approximately $731,000. Finally, Geode Capital Management LLC increased its holdings in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after buying an additional 12,896 shares during the last quarter. Hedge funds and other institutional investors own 17.51% of the company's stock.

More vTv Therapeutics News

Here are the key news stories impacting vTv Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $42 price target for vTv Therapeutics. The target remains above the stock’s recent trading level, signaling that the analyst sees potential upside tied to the company’s biotechnology pipeline. HC Wainwright Cuts vTv Therapeutics Price Target to $42.00
• Neutral Sentiment: HC Wainwright’s $42 target is unchanged, but its revised estimates indicate that the company may continue reporting substantial losses. The analyst now expects 2026 earnings of ($0.97) per share, compared with a previous estimate of $0.02, and projects losses through 2030. HC Wainwright earnings estimates for vTv Therapeutics
• Negative Sentiment: HC Wainwright lowered its quarterly forecasts to losses of ($1.01) per share for Q3 2026 and ($0.89) for Q4 2026. Longer-term estimates were also reduced, including 2027 EPS to ($4.60), 2028 EPS to ($4.40), 2029 EPS to ($3.78), and 2030 EPS to ($3.61). The cuts suggest higher expected expenses or a slower path toward profitability. HC Wainwright lowers vTv Therapeutics earnings estimates
• Negative Sentiment: Wall Street Zen downgraded VTVT to Sell, adding bearish pressure to the investment outlook. The downgrade is especially notable because vTv Therapeutics recently reported a quarterly loss that was wider than analysts expected. vTv Therapeutics downgraded by Wall Street Zen to Sell

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source